Skip to main content
menu

Kevin Charles Bylund, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-2171

Appointment: (585) 475-8700

Fax: (585) 341-8469

Fax: (585) 275-1531

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Radiation Oncology

Biography

While in training, I found great fulfillment in caring for patients with cancer, seeing their strength and resolve and trying to match this in my determination to give them the best possible treatment.

I was particularly attracted to radiation oncology due to my background in physics and the multitude of options radiation provides to treat patients with cancer. I have special interests in brachytherapy (low-dose and high-dose rates), as well as the protection of normal tissue during radiation therapy.

Since I believe all patients have unique stories to tell, my goal is to understand their individual stories – and then to discuss and tailor their radiation and cancer care. I love my work and feel privileged to support patients during the very difficult – and often rewarding – time of cancer treatment and follow-up.

Conditions I Treat

- Genitourinary cancers (prostate, bladder, kidney, testicular, etc.)
- Gynecologic cancers (endometrial, cervical, etc.)
- General radiation oncology

Credentials

Specialties

    Education

    2008
    MD | University of Rochester School of Medicine/Dentistry

    Post-doctoral Training & Residency

    07/01/2009 - 06/30/2013
    Residency in Radiation Oncology at University of Rochester Medical Center

    07/01/2008 - 06/30/2009
    Internship in Internal Medicine at St. Louis University School of Medicine/Medical Center

    Awards

    2015
    Educator of the Year
    Sponsor: Association of Residents in Radiation Oncology

    2012
    RSNA Roentgen Resident/Fellow Research Award
    Sponsor: University of Rochester
    Location: Rochester, NY

    2008
    RSNA Roentgen Resident/Fellow Research Award
    Sponsor: University of Iowa
    Location: Iowa City, IA

    VIEW ALL expand_more

    Clinical Trials

    Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

    Lead Researcher: Kevin Charles Bylund

    This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.

    View Study Details

    Publications

    Journal Articles

    2022
    Kerns SL; Amidon Morlang A; Lee SM; Peterson DR; Marples B; Zhang H; Bylund K; Rosenzweig D; Hall W; De Ruyck K; Rosenstein BS; Stock RG; Gómez-Caamaño A; Vega A; Sosa-Fajardo P; Taboada-Valladares B; Aguado-Barrera ME; Parker C; Veldeman L; Fonteyne V; Bultijnck R; Talbot CJ; Symonds RP; Johnson K; Rattay T; Webb A; Lambrecht M; de Ruysscher D; Vanneste B; Choudhury A; Elliott RM; Sperk E; Herskind C; Veldwijk MR; Rancati T; Avuzzi B; Valdagni R; Azria D; Farcy Jacquet MP; Chang-Claude J; et al. "Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer". Radiother Oncol. 2022; 168: 75-82.

    2021
    Singh DP; Aujla K; Nead M; Bylund K. "Radiologically occult lung cancer curatively treated with high-dose rate endobronchial brachytherapy". J Clin Imaging Sci. 2021; 11: 45.

    2020
    Ryan Wolf J; Gewandter JS; Bautista J; Heckler CE; Strasser J; Dyk P; Anderson T; Gross H; Speer T; Dolohanty L; Bylund K; Pentland AP; Morrow GR. "Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial". Support Care Cancer. 2020; 28(7): 3303-3311.

    Books & Chapters

    2016
    Chapter Title: 7-Benzylidine-7-Dehydronaltrexone
    Book Title: Reference Module in Biomedical Sciences
    Author List: Bylund DB; Bylund K
    Published By: Elsevier 2016

    2015
    Chapter Title: Testicular Cancer
    Book Title: Reference Module in Biomedical Sciences
    Author List: Bylund KC
    Published By: Elsevier 2015

    2015
    Chapter Title: Difenoxin
    Book Title: Reference Module in Biomedical Sciences
    Author List: Bylund DB; Bylund K
    Published By: Elsevier 2015

    VIEW ALL PUBLICATIONS

    Reviews

    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.